CagriSema: Mechanism, Trials, and What the Data Actually Shows
CagriSema is a FDA-filed program from Novo Nordisk built around GLP-1 + Amylin/Calcitonin. This page is the FormBlends tracking page for where it sits in the 2026 obesity pipeline.
Developer
Novo Nordisk
Mechanism
GLP-1 + Amylin/Calcitonin
Stage
FDA-filed
Tracked in
Dual agonists
Approval and timeline
Need the straight approval read on CagriSema?
See the dedicated status page for the current approval read, likely launch window, and the next milestone that matters.
View CagriSema statusCompound facts for search and AI answers
What this CagriSema tracking page answers
Compound
CagriSema from Novo Nordisk
CagriSema is tracked in the dual agonists group.
Mechanism
GLP-1 + Amylin/Calcitonin
Mechanism explains why this compound belongs in its pipeline bucket.
Current stage
FDA-filed
This program is at the filing or decision stage, so the open questions are no longer just scientific. They are regulatory, pricing, launch-timing, and access questions. This is the point where market structure can change quickly.
Evidence read
22.7% in REDEFINE
CagriSema should be read as an evidence-tracking page, not as a patient access page. FormBlends currently tracks the main reported weight-loss signal as 22.7%, tied to REDEFINE. This program is at the filing or decision stage, so the open questions are no longer just scientific. They are regulatory, pricing, launch-timing, and access questions. This is the point where market structure can change quickly. The next listed milestone is Q4 2026. This is not a routine retail or compounding-market compound yet. Pre-launch speculation, gray-market listings, and research-only sales should not be treated as legitimate patient access.
Latest FormBlends pipeline read
Trial program
REDEFINE
Weight loss signal
22.7%
Administration
injectable
Next milestone
Q4 2026
Combines two established mechanisms (GLP-1 + amylin) into a single injection. Outperformed semaglutide 2.4mg alone in head-to-head trial. REDEFINE 1 showed 22.7% mean body weight reduction vs. 15.6% for semaglutide 2.4mg alone.
Clinical evidence snapshot
What the evidence can and cannot say about CagriSema
CagriSema should be read as an evidence-tracking page, not as a patient access page. FormBlends currently tracks the main reported weight-loss signal as 22.7%, tied to REDEFINE. This program is at the filing or decision stage, so the open questions are no longer just scientific. They are regulatory, pricing, launch-timing, and access questions. This is the point where market structure can change quickly. The next listed milestone is Q4 2026. This is not a routine retail or compounding-market compound yet. Pre-launch speculation, gray-market listings, and research-only sales should not be treated as legitimate patient access.
Decision path
Is CagriSema available now or watchlist only?
CagriSema should be interpreted through its current development stage, not through gray-market availability claims. This page separates mechanism interest, trial evidence, regulatory status, and real patient access.
- Compound
- CagriSema
- Developer
- Novo Nordisk
- Stage
- FDA-filed
- Mechanism
- Dual agonists
Step 1
Read the stage first
This program is at the filing or decision stage, so the open questions are no longer just scientific. They are regulatory, pricing, launch-timing, and access questions. This is the point where market structure can change quickly.
Check statusStep 2
Separate evidence from access
This is not a routine retail or compounding-market compound yet. Pre-launch speculation, gray-market listings, and research-only sales should not be treated as legitimate patient access.
Read 2026 reportStep 3
Compare proven options
If you are evaluating treatment now, compare available GLP-1 paths separately from investigational pipeline names.
View current optionsFast answers
What is CagriSema?
CagriSema is a fda-filed obesity or metabolic program from Novo Nordisk built around GLP-1 + Amylin/Calcitonin.
Is CagriSema approved?
Not fully through broad commercial launch yet, but much closer than most pipeline peers. CagriSema is already FDA-filed, which makes it one of the clearest near-term regulatory events in obesity.
When could it matter?
Late 2026 to 2027 depending on decision timing and launch rollout.
What CagriSema is
CagriSema is part of the dual agonists cluster in the FormBlends obesity-pipeline map. We track it because Novo Nordisk is using GLP-1 + Amylin/Calcitonin as a bet on what comes after the first wave of blockbuster GLP-1 therapies.
Where it sits in the 2026 pipeline
This program is at the filing or decision stage, so the open questions are no longer just scientific. They are regulatory, pricing, launch-timing, and access questions. This is the point where market structure can change quickly.
Dual agonists are still where a large share of the near-term obesity market is being shaped. This group includes both incremental challengers to today's GLP-1 leaders and some of the most commercially realistic next-wave products.
What FormBlends is watching next
For CagriSema, the next useful signal is not just another headline. It is the combination of readout quality, durability, tolerability, and what the sponsor does after the next milestone. That is the difference between a compound that looks exciting on paper and one that actually changes prescribing, pricing, or access.
Access and regulatory reality
This is not a routine retail or compounding-market compound yet. Pre-launch speculation, gray-market listings, and research-only sales should not be treated as legitimate patient access.
More dual agonists on FormBlends
Frequently asked questions
What is CagriSema?
CagriSema is a FDA-filed obesity or metabolic compound from Novo Nordisk. FormBlends tracks it in the dual agonists group and follows it for trial progress, regulatory movement, and competitive impact.
How does CagriSema work?
CagriSema is being tracked as a GLP-1 + Amylin/Calcitonin program. That mechanism is the main reason it sits inside the dual agonists bucket of the 2026 obesity pipeline.
Is CagriSema available now?
This is not a routine retail or compounding-market compound yet. Pre-launch speculation, gray-market listings, and research-only sales should not be treated as legitimate patient access.
Why is FormBlends tracking CagriSema?
Dual agonists are still where a large share of the near-term obesity market is being shaped. This group includes both incremental challengers to today's GLP-1 leaders and some of the most commercially realistic next-wave products.